Department of Radiology, Osaka Medical College, Takatsuki-City, Osaka, Japan.
Department of Radiology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan
Anticancer Res. 2014 Jun;34(6):3077-81.
To examine the role of the new grading system Prostate Cancer Risk Index (PRIX) with existing risk-grouping after high-dose-rate interstitial brachytherapy (HDR-ISBT) as monotherapy for localized prostate cancer.
We analyzed outcome in 100 patients treated by HDR-ISBT as monotherapy using PRIX and compared this with D'Amico, the National Comprehensive Cancer Network (NCCN), and Seattle classifications. The median follow-up was 74 (range=48-109) months.
Five-year prostate-specific antigen control and overall survival rates were 94% and 98%, respectively. PRIX separated the risks statistically significantly (p=0.004), while D'Amico (p=0.319), NCCN 2002 (p=0.126), NCCN 2012 (p=0.052) and Seattle (p=0.112) classifications failed to show a statistically significant separation.
PRIX is a more useful risk classification system in high-risk patient selection than existing risk classification system in clinically localized prostate cancer after HDR-ISBT as monotherapy.
探讨新的分级系统前列腺癌风险指数（PRIX）在高危局限性前列腺癌患者接受高剂量率间质近距离治疗（HDR-ISBT）单药治疗后的作用。
我们分析了 100 例接受 HDR-ISBT 单药治疗的患者的结果，使用 PRIX 进行分析，并与 D'Amico、美国国家综合癌症网络（NCCN）和西雅图分类进行比较。中位随访时间为 74 个月（范围 48-109）。
5 年前列腺特异性抗原控制率和总生存率分别为 94%和 98%。PRIX 在统计学上显著分离了风险（p=0.004），而 D'Amico（p=0.319）、NCCN 2002（p=0.126）、NCCN 2012（p=0.052）和西雅图（p=0.112）分类未能显示出统计学上显著的分离。
在高危局限性前列腺癌患者接受 HDR-ISBT 单药治疗后，PRIX 是一种比现有风险分类系统更有用的风险分类系统。
